Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

Benzinga Newsdesk www.benzinga.com Negative 95.4%

Neg 95.4% Neu 0% Pos 0%

Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $44 to $34.